HK Stock Connect Insight | BOAN BIOTECH (06955.HK) Market Cap Falls to HKD 1.872 Billion After Stock Connect Exit; 6.90 Million Shares Repurchased in September
- BOAN BIOTECH listed on the HKEX Main Board on December 30, 2022 at HKD 19.800 per share, offering 10,694,800 H shares and raising about HKD 152.8 million net, with three cornerstone investors taking about 71.01% of the global offering; it joined Stock Connect on March 13, 2023.
- First-half 2026 gross margin was 62.66%, down 9.17 percentage points, and R&D costs rose 57.09% to RMB 92.01 million; cash and cash equivalents were RMB 1.106 billion and the current ratio was 1.74.
- Boyoubei was approved in Bolivia, dulaglutide was approved in Macao and a new indication for Boluojia was approved by the NMPA this year; the BLAs for the two denosumab products were accepted by the US FDA in July.
On November 13, 2026, BOAN BIOTECH edged higher; as of 13:47, the stock was quoted at HKD 3.050, up 1.50%, with a turnover of about HKD 529,400 and a market capitalisation of about HKD 1.872 billion based on the latest price.
Data show that BOAN BIOTECH's share price remained under pressure over the past week (November 7 to November 13). The stock touched an intraday low of HKD 2.955 during the session.
Over a longer period, BOAN BIOTECH fell about 1.13% in the past month, about 34.13% in the past three months and about 71.50% over the past 52 weeks. The stock has retreated continuously since its listing in December 2022, and its current market capitalisation of HKD 1.872 billion is about 47% of the HKD 4 billion threshold under the Stock Connect small-cap removal rule.
On September 7, 2026, the Hang Seng Composite Index rebalancing took effect, and BOAN BIOTECH (06955.HK) was removed from the Hang Seng Composite Index and accordingly removed from Stock Connect. From the effective date, mainland Stock Connect investors may only sell and cannot open new purchases.
It is understood that BOAN BIOTECH listed on the Main Board of HKEX on December 30, 2022 at an offer price of HKD 19.800, offering 10,694,800 H shares globally and raising net proceeds of about HKD 152.8 million; the company listed directly on the HKEX Main Board and is not an A+H structure. Three cornerstone investors—Fu Heliang, Harvest Great Bay Investment SP and Sino Biopharmaceutical—subscribed a total of 7,594,000 shares for about HKD 150.4 million, representing about 71.01% of the global offering. On March 3, 2023, the Shenzhen Stock Exchange published an adjustment notice for the Stock Connect eligible securities list, and the company was added to Stock Connect with effect from March 13, 2023. Based on the latest disclosure, the company has 613,633,694 issued shares.
In terms of historical share price performance, the company was included in Stock Connect on March 13, 2023, closing at HKD 14.760 that day. As expectations of centralised procurement for biosimilars intensified and revenue declined, the share price fell continuously; its current market capitalisation of HKD 1.872 billion is about 81% below the HKD 10.084 billion recorded on its first trading day.
Public information shows that BOAN BIOTECH's principal business is the development, manufacturing and commercialisation of biologics, focused on oncology, metabolic, autoimmune and ophthalmic therapeutic areas, with five products already launched: Boyounuo (bevacizumab), Boyoubei (60mg denosumab), Boluojia (120mg denosumab), Boyouping (dulaglutide) and Boyoujing (aflibercept). In the first half of 2026, product sales revenue was RMB 213 million, or 91.25% of total revenue; licensing revenue was RMB 18.16 million, or 7.79%; and research service revenue was RMB 2.234 million, or 0.96%.
In the first half of 2026, the company's revenue was RMB 233 million, down 40.77% year on year; gross profit was RMB 145.9 million, down 48.3%, with a gross margin of 62.66%, down 9.17 percentage points; R&D costs were RMB 92.01 million, up 57.09%; selling and distribution expenses were RMB 107.1 million, down 32.97%; administrative expenses were RMB 15.46 million, down 33.29%; the loss for the period was RMB 83.009 million, compared with a profit of RMB 20.514 million a year earlier; and basic loss per share was RMB 0.13.
On the overseas side, the BLAs for the company's two denosumab injections were submitted to the US FDA in May 2026 and accepted for review in July, with approval in the United States expected in the first half of 2027; both products are also under review by the UK MHRA. As at June 30, the company held cash and cash equivalents of RMB 1.106 billion, with net current assets of RMB 818 million and a current ratio of 1.74.
On products and business developments, BOAN BIOTECH obtained approval in Bolivia for Boyoubei in January this year; in May, dulaglutide was approved in Macao and a new indication for Boluojia was approved by the National Medical Products Administration; in July, the Phase II clinical trial application for BA1106 combined with BA1104 was approved by the Center for Drug Evaluation, and the IND application for BA1203 was accepted in the same month.
HUAAN SECURITIES noted in a research report that BOAN BIOTECH's biosimilars form the revenue base, the revenue share of products other than Boyounuo has continued to rise, and overseas commercialisation has moved from planning to delivery, with the two denosumab products having completed multinational Phase III trials in Europe, the United States and Japan and set to file a US BLA; within the innovative pipeline, BA1106 is the first non-IL-2 blocking anti-CD25 antibody in clinical development in China and BA1302 has received FDA orphan drug designation, giving the pipeline licensing potential overseas.
- HK Stock Connect Insight | BIDU-W (09888.HK) -18%; Dual Listing Sep 1
- HK Stock Connect Insight | IFBH (06603.HK) Market Cap Falls to HKD 887 Million After Stock Connect Exit; 175 Million Escrow Shares Unlocked on June 30
- HK Stock Connect Insight | METIS TECHBIO-P (07666.HK): Southbound stake rises to 5.94% after Stock Connect inclusion on Sept 7
- HK Stock Connect Insight | HEALTHYWAY INC (02587.HK) Market Cap Slides to HKD 599 Million After Stock Connect Exit; Interim Revenue Rose 49.7% to RMB 775 Million
- HK Stock Connect Insight | XUNLONG SCITECH (06715.HK): Southbound stake rises to 0.99% after Stock Connect inclusion on Sept 7